Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Crystagen4 residuesAEDREach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Crystagen, Kristagen
Three amino acids. That's all Crystagen is. Glu-Asp-Pro, a synthetic tripeptide pulled from Thymalin, the Soviet-era thymus extract that's been in Russian clinical use since 1982. In one clinical observation of elderly patients, oral Crystagen normalized immunograms in 82% of cases after a 30-day course. That number sounds good until you learn it comes from a single research group at the St. Petersburg Institute of Bioregulation and Gerontology, with no independent Western replication. The peptide is taken as oral capsules (20 mg, once daily) for 10 to 30 days, repeated two to three times per year. Longevity protocol users stack it with Epithalon for combined thymic and pineal axis coverage.
Four published studies, one research group, and an 82% immunogram normalization rate that nobody outside St. Petersburg has tried to replicate. That's the honest picture of Crystagen (Glu-Asp-Pro, molecular weight ~345 Da, No CAS number assigned), a synthetic tripeptide isolated from Thymalin at the Khavinson Institute of Bioregulation and Gerontology. The mechanism targets immune cell gene expression. Crystagen's Glu-Asp dipeptide core binds DNA promoter regions in thymic epithelial cells and lymphocytes, promoting heterochromatinization of aged chromatin. In thymocyte assays, Khavinson's group tracked shifts in CD3+ and CD4+ T-cell populations and normalization of CD4+/CD8+ ratios [1]. In gamma-irradiated rat models, the peptide preserved thymic cortex-medulla architecture and maintained thymocyte proliferation. Practically, Crystagen is an oral capsule. One to two capsules daily (20 to 40 mg), taken 15 to 20 minutes before a meal, for courses of 10 to 30 days. Courses repeat two to three times per year with three to six month breaks between them. Oral bioavailability sits at an estimated 1 to 10% based on general tripeptide pharmacokinetics; Khavinson's group argues that even minimal absorption triggers gene-regulatory cascades that persist beyond the dosing period. Community experience is thin. Fewer than 10 independent Reddit threads discuss Crystagen. Most user reports come from vendor testimonials and a single longevity blog. Anecdotal benefits center on immune resilience during cold and flu season, though separating this from placebo is essentially impossible without bloodwork. The peptide's research base is real but narrow, and the single-group dependency is the biggest scientific limitation.
Crystagen belongs to the Khavinson class of ultrashort peptides proposed to regulate gene expression through direct DNA interaction. The peptide's tissue specificity for immune cells appears to come from its Glu-Asp dipeptide core, which binds specific gene promoter regions in thymic epithelial cells and blood lymphocytes. In the spleen, Crystagen activates B-cell immunity without affecting cellular renewal processes during aging. This distinguishes it from Vilon (Lys-Glu), which primarily targets T-helper cells [2]. In thymocyte assays, the peptide influences T-cell differentiation markers. Khavinson's group reported shifts in CD3+ and CD4+ populations and normalization of CD4+/CD8+ ratios in elderly subjects [1]. At the epigenetic level, Crystagen promotes heterochromatinization in aged lymphocytes. Chromatin condensation patterns in blood lymphocytes from elderly subjects shifted toward younger profiles after a full treatment course [3]. This suggests the peptide can alter gene accessibility states, though the downstream functional consequences of these chromatin changes have not been mapped in detail. The proposed model is that short peptide courses trigger lasting epigenetic reprogramming that persists for months. This differs from receptor desensitization or hormonal axis feedback models. The peptide doesn't accumulate; it initiates a cascade.
Preclinical immune modulation data from a single Russian research group; 82% immunogram normalization reported in one elderly-patient clinical observation. No independent Western replication exists. Oral bioavailability estimated at 1–10% with no direct PK studies.
Khavinson et al. 2002 (PMID 12420072): thymocyte blast transformation and CD3+/CD4+ signal transduction; Khavinson et al. 2004 (PMID 15085253): lymphocyte heterochromatinization in elderly subjects
All published data originates from a single research group (Khavinson Institute, St. Petersburg). No RCTs, no independent replication, no Western peer review, no direct PK studies on Crystagen itself. Oral bioavailability is estimated by analogy to tripeptide class pharmacokinetics, not directly measured.
Extremely limited independent user reports: most accounts appear on vendor sites. Anecdotal immune resilience during cold/flu season and nootropic clarity (when stacked with other Khavinson bioregulators) are the primary reported benefits.
Science and community both identify immune modulation as the primary use case. Community anecdotes extend to nootropic/clarity effects not reported in any published study. Dosing broadly matches the Khavinson 1–2 capsule/day protocol, though community use sometimes defaults to continuous daily use rather than the structured 10–30 day course model.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 20mg | Daily |
| Moderate | 40mg | Daily |
| Aggressive | 20mg | 2x Daily |
Crystagen comes as oral capsules, so there's no reconstitution math. Each capsule contains 20 mg of the synthetic tripeptide (Glu-Asp-Pro). Take one capsule 15 to 20 minutes before a meal, once daily, for 30 days. Swallow whole with water. The thing most beginners miss: you won't feel anything. Crystagen works through epigenetic changes in immune cells that accumulate over 15 to 30 days. Lack of immediate effect is normal, not a sign of a bad product. Bloodwork is the only way to know if it worked. Get a CBC with differential and CD4+/CD8+ ratio before starting, then retest four to six weeks after finishing the course. Subjective "feeling healthier" is unreliable for immune peptides. Source your capsules from Khavinson-affiliated vendors (CosmicNootropic, iPept, Antiaging Systems). Look for CYTOGENS branding with Russian-language primary labeling. Avoid injectable vials sold by research peptide vendors; that format has zero clinical backing.
Standard Khavinson bioregulator protocol: 10-30 day courses repeated 2-3 times per year. A common regimen is 1-2 capsules daily for 30 days, then a 3-6 month break.
Khavinson's epigenetic bioregulator model proposes that short peptide courses (10–30 days) trigger lasting changes in immune cell gene expression that persist for months without continued dosing. The mechanism is not dose-accumulation dependent: the peptide initiates epigenetic reprogramming that becomes self-sustaining. The 3–6 month off-period is structural: it allows the body to maintain the corrected gene expression pattern and confirms that repeat stimulation is needed before administering the next course. This differs fundamentally from receptor desensitization, antibody formation, or hormonal axis recovery models.
Or use the universal Peptide Calculator for any peptide.
Expected: Potential normalization of CD4+/CD8+ ratio and lymphocyte counts after a full 30-day course per Khavinson data; subjective immune resilience during cold/flu season per community reports
Monitor: Baseline CBC with differential and CD4+/CD8+ ratio before starting; retest 4–6 weeks after course completion to assess objective immune response
Check for Russian-language labeling and lot number on the packaging.
Swallow whole with water. Do not crush or open the capsule.
The standard beginner course is one capsule (20 mg) per day.
Do not skip days or double up on missed doses.
The standard off-period is three to six months. During this break, the epigenetic changes from the course are expected to persist.
An intermediate protocol starts with one capsule daily for two weeks, then increases to two capsules (40 mg) daily for the remaining two weeks.
Storage: keep capsules at room temperature (15 to 25 degrees Celsius) in a dry place, away from direct sunlight. No refrigeration needed.
1–2 capsules (20–40 mg) once daily, 15–20 minutes before a meal
Standard CYTOGENS format from authorized Khavinson vendors. Bioavailability estimated at 1–10% by analogy to tripeptide class; Khavinson argues this is sufficient to trigger gene-regulatory cascades without high systemic concentrations.
1 mL/day (10 mg/mL solution) administered as 5–6 drops, 3–4 times daily per product label instructions
Sold by Antiaging Systems, QiSupplements, vita-stream. Sublingual bypass of first-pass metabolism theoretically improves bioavailability over oral capsule, but this has not been studied for Crystagen. Timing and dosing protocol differs from the oral capsule format.
No established injectable dosing protocol; vials sold as research use only with no clinical dosing reference
Injectable format is not a Khavinson Institute product and has no clinical precedent. Community occasionally uses based on dosing models extrapolated from other injectable thymic peptides: entirely speculative. Significantly higher risk profile than oral/sublingual.
Parent thymic polypeptide extract (IM) + Crystagen (synthetic oral tripeptide): broader thymic peptide coverage combining a complex natural extract with a defined single cytogen. Frequently paired in the Khavinson longevity bioregulator protocol.
Sequential or concurrent courses per Khavinson bioregulator protocol guidelines
Classic Khavinson longevity stack: Epithalon targets the pineal/telomerase axis; Crystagen targets the thymic/immune axis. Combined use mirrors the design of the 266-person 6–8 year mortality reduction study.
Complementary thymic immune support with far stronger clinical evidence (Western RCTs, antiviral data). Crystagen adds Khavinson-protocol gene-regulatory thymic signaling; TA-1 adds documented T-cell activation and antiviral efficacy.
Additive thymic hormonal support: Thymulin (circulating thymic hormone) and Crystagen (gene-regulatory tripeptide) operate via distinct mechanisms. Occasionally stacked in longevity-focused protocols covering multiple aspects of thymic function.
Crystagen's immune-activating effects directly oppose immunosuppressive therapy. Risk of undermining transplant rejection protection or active autoimmune disease management.
Do not combineCombined immune activation from checkpoint inhibition + Crystagen is completely unstudied. Theoretical compounding of immune-related adverse events (irAEs) in oncology patients.
Do not combinePricing updated 2026-04-09
The biggest concern with Crystagen isn't a specific side effect. It's the absence of data. No adverse effects directly attributable to Crystagen have been reported in any published study, but the total safety database is small (five publications, all from a single group, with limited patient counts). Autoimmune exacerbation is the most clinically relevant theoretical risk. Crystagen activates T-cell and B-cell populations and shifts CD4+/CD8+ ratios. In someone with subclinical or active autoimmune disease, this immune stimulation could unmask or worsen autoimmune flares. Joint swelling, unexplained rash, or new symptom patterns during a course warrant immediate discontinuation and medical evaluation before restarting. Gastrointestinal discomfort is possible with the oral capsule formulation. Taking Crystagen 15 to 20 minutes before a meal (not on a fully empty stomach) reduces GI irritation. This is the most commonly reported practical issue in user accounts, though severity appears mild. Immunosuppressant interference is a serious drug interaction concern. Crystagen's immune-activating effects directly oppose cyclosporine, tacrolimus, and similar immunosuppressive therapy. Organ transplant recipients on immunosuppression should not use Crystagen. The risk of undermining transplant rejection protection is real and straightforward. Checkpoint inhibitor interactions are completely unstudied. For oncology patients on pembrolizumab, nivolumab, or ipilimumab, adding Crystagen introduces combined immune activation with unknown immune-related adverse event profiles. This combination should be avoided. Oral bioavailability uncertainty adds another layer. Absorption is estimated at 1 to 10% based on tripeptide class pharmacokinetics, not direct measurement. Batch-to-batch variation across vendors (capsules range from 10 mg to 20 mg depending on supplier) means actual dose delivered to systemic circulation is unpredictable. Pregnancy and breastfeeding are absolute contraindications. No reproductive safety data exists for Crystagen. Given the peptide's mechanism of modulating immune cell gene expression, use during pregnancy or breastfeeding is not appropriate. Quality control is a practical safety concern. Authentic CYTOGENS brand capsules from Khavinson-affiliated vendors (CosmicNootropic, iPept) have established manufacturing history. Research-vendor injectable vials from Umbrella Labs or RCPeptides represent a separate, higher-risk supply chain with no clinical precedent for the injectable format. Avoid injectable versions; the oral capsule is the only format with clinical backing. Stop the course and seek medical evaluation if: new joint swelling or unexplained rash appears, fever develops without an obvious infection source, or any autoimmune symptom pattern emerges. Do not start a new course during active infection or fever.
Verify Crystagen dosing and safety with a second opinion
Oral capsules from Khavinson-affiliated Russian manufacturers (CYTOGENS brand sold via CosmicNootropic, iPept, Antiaging Systems) have an established manufacturing history but lack Western GMP certification or publicly available third-party CoA documentation. Research-vendor injectable vials (Umbrella Labs 10 mg, RCPeptides 20 mg) represent a separate, higher-risk supply chain with no clinical precedent for the injectable format and no Khavinson program affiliation.
| Test | When | Target |
|---|---|---|
| CBC with differential (absolute lymphocyte count) | Baseline before course; repeat 4–6 weeks after course completion | Normal absolute lymphocyte count 1.0–4.8 × 10⁹/L (age-adjusted reference ranges apply) |
| CD4+/CD8+ T-cell ratio (flow cytometry) | Baseline and end of course (day 30) | Normal CD4+/CD8+ ratio: 1.5–2.5; values <1.0 indicate significant immune suppression |
| ANA (antinuclear antibody) screen | Baseline; repeat only if new autoimmune symptoms emerge during or after course | — |
Primary objective measure of Crystagen immune effect; lymphocyte normalization is the claimed clinical endpoint in Khavinson literature
Key immune parameter reported in Khavinson studies; Crystagen specifically claimed to normalize this ratio in elderly individuals
Immune activation via Crystagen carries theoretical risk of unmasking or exacerbating subclinical autoimmune conditions
Course initiation. No outward immune changes expected in this early window.
Short peptides begin influencing gene expression in immune cells. Subtle shifts in immune cell populations may begin, though unlikely to be noticeable without bloodwork.
End of standard course. The 82% immunogram normalization figure was observed after full treatment courses in elderly patients.
The Khavinson theory holds that short peptide effects persist well beyond the dosing period. The off-cycle allows assessment of whether immune improvements are maintained.
Days 1 to 5, Course initiation: Nothing happens that you can feel. The peptide is beginning to interact with gene promoter regions in immune cells per Khavinson's epigenetic model, but measurable immune changes haven't started yet. Users universally report no noticeable effects in this window. Mild GI discomfort is possible if you take the capsule on an empty stomach; eat within 20 minutes of dosing. Days 5 to 15, Gene expression accumulation: Epigenetic changes in thymic epithelial cells and lymphocytes are building. T-cell differentiation markers (CD3+, CD4+) should begin shifting if the mechanism is active, but you can't detect this without bloodwork. A small number of users report subtle energy or clarity improvements when stacking with other Khavinson bioregulators, though separating this from placebo is difficult. Days 15 to 30, End of standard course: This is where the published data lives. Khavinson's clinical observation reported 82% immunogram normalization (CD4+/CD8+ ratio) after full treatment courses in elderly patients, compared to 56% in the standard-treatment control group. Some community users describe feeling "more resilient" to illness; independent verification of these subjective reports is essentially absent. Months 1 to 6 post-course, Carry-over period: The off-cycle. Khavinson's model holds that epigenetic changes in immune cells persist well beyond the dosing period. The three to six month break lets you confirm that immune improvements are self-sustaining before the next course. Independent data on carry-over duration is minimal. Longevity protocol users report continued immune stability for months, though attributing this specifically to Crystagen is difficult.
No measurable immune changes yet. Peptide begins interacting with immune cell gene promoter regions per Khavinson epigenetic model.
Users universally report no noticeable effects in the first few days: consistent with the slow epigenetic mechanism.
Epigenetic changes in thymic epithelial cells and lymphocytes begin to accumulate. T-cell differentiation markers (CD3+, CD4+) should begin shifting if the mechanism is active.
A minority of users report early subtle improvements in energy or mental clarity when stacked with other bioregulators; most report no change. Difficult to distinguish from placebo.
82% immunogram normalization (CD4+/CD8+ ratio) reported at end of full treatment course in elderly patients in Khavinson clinical observation (vs. 56% in standard-treatment control group).
Some users report feeling "more resilient" to illness; anecdotal immune resistance to cold/flu reported via vendor testimonials. Independent verification essentially absent.
Khavinson theory holds that epigenetic changes in immune cells persist well beyond the dosing period. The 3–6 month off-period allows assessment of whether immune improvements are self-sustaining.
Minimal independent data. Longevity-protocol users report continued immune stability for months post-course, though this is difficult to attribute specifically to Crystagen.
Source: Estimated from ultrashort peptide kinetics; no direct PK studies on Crystagen published.
Loading the interactive decay curve.
Crystagen is classified as a dietary supplement (bioregulator) in Russia and several CIS countries. It is not FDA-approved in the United States and has not undergone FDA review for safety or efficacy. The peptide is sold as a research compound or supplement through international vendors. Crystagen is not listed on the WADA Prohibited List, though athletes should verify current status with their specific governing body before use. No pending regulatory changes or scheduling actions for Crystagen have been identified in US, EU, or UK regulatory databases. The peptide remains available through specialty supplement vendors and research peptide suppliers. This content is for informational purposes only and does not constitute medical advice. Crystagen has not been approved by any Western regulatory agency for the prevention, treatment, or cure of any disease. Consult a qualified healthcare provider before starting any peptide protocol.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
